PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO

Prescription Drug User Fee Act negotiations should address the discrepancy in FDA performance on approval times for standard and priority review applications, Biotechnology Industry Organization's Amit Sachdev said